Liquidia Corporation

Liquidia Corporation

LQDA·NASDAQ

$55.69

+1.5%
HealthcareBiotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

At a Glance

Live Snapshot
Market Cap$4.95B
EPS-0.8000
P/E Ratio-69.61
Earnings Date08/11/2026

lqda

Net Cash Provided by Financing Activities

Last Annual Value

59.73M

3-Year CAGR

-3%

5-Year CAGR

-1%

10-Year CAGR

26%

Liquidia Corporation

Liquidia Corporation Competitors Analysis of Net Cash Provided by Financing Activities

LQDA · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
59.73M
11.4%17.8%25.6% 
878.23M
75.1%87.4%N/A
762.52M
19.1%49.2%N/A
189.22M
119.8%57.8%-4.5%
ETNB logo
89bio, Inc.
NASDAQ:ETNB
218.59M
-24.8%55.7%N/A
400.24M
-10.5%-4.6%N/A
488.00M
145.5%15.5%21.4%
561.72M
49.0%187.7%98.7%
8.68M
16.9%N/A-25.7%
Liquidia Corporation

Liquidia Corporation Fair Value Envelope

LQDA · NASDAQ

Our analysis suggests that LQDA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $55.69, this represents a potential HIDDEN relative to our calculated worth for Liquidia Corporation.

Intrinsic Value
Current Price: $55.69